Baird Financial Group Inc. Increases Position in Exact Sciences Co. (NASDAQ:EXAS)

Baird Financial Group Inc. raised its position in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 2.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 335,980 shares of the medical research company's stock after buying an additional 9,045 shares during the quarter. Baird Financial Group Inc. owned about 0.18% of Exact Sciences worth $18,879,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the company. Asset Planning Inc purchased a new position in shares of Exact Sciences in the fourth quarter valued at $40,000. AlphaQuest LLC grew its stake in shares of Exact Sciences by 22,825.0% in the 4th quarter. AlphaQuest LLC now owns 917 shares of the medical research company's stock worth $52,000 after buying an additional 913 shares in the last quarter. SBI Securities Co. Ltd. bought a new stake in shares of Exact Sciences in the 4th quarter worth about $66,000. Ostrum Asset Management raised its position in shares of Exact Sciences by 28.4% during the 4th quarter. Ostrum Asset Management now owns 2,382 shares of the medical research company's stock valued at $134,000 after buying an additional 527 shares in the last quarter. Finally, Kieckhefer Group LLC bought a new position in shares of Exact Sciences in the 4th quarter valued at about $188,000. Institutional investors own 88.82% of the company's stock.

Exact Sciences Stock Down 2.5 %

Shares of EXAS traded down $1.34 during trading hours on Friday, hitting $51.72. The company had a trading volume of 1,975,218 shares, compared to its average volume of 2,613,726. The company has a market capitalization of $9.76 billion, a PE ratio of -9.29 and a beta of 0.92. The company has a current ratio of 2.15, a quick ratio of 1.93 and a debt-to-equity ratio of 0.97. The company's fifty day moving average price is $45.52 and its two-hundred day moving average price is $52.83. Exact Sciences Co. has a one year low of $39.97 and a one year high of $72.83.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical research company reported ($0.21) EPS for the quarter, beating analysts' consensus estimates of ($0.37) by $0.16. The company had revenue of $706.79 million during the quarter, compared to analysts' expectations of $688.58 million. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. Exact Sciences's revenue for the quarter was up 10.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.60) earnings per share. As a group, equities analysts forecast that Exact Sciences Co. will post -0.58 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Royal Bank of Canada boosted their price objective on Exact Sciences from $52.00 to $54.00 and gave the stock a "sector perform" rating in a research note on Friday, May 2nd. Scotiabank increased their price target on Exact Sciences from $70.00 to $73.00 and gave the company a "sector outperform" rating in a report on Monday, February 24th. Barclays raised their price target on Exact Sciences from $55.00 to $75.00 and gave the stock an "overweight" rating in a research report on Friday, May 2nd. Mizuho started coverage on shares of Exact Sciences in a research note on Thursday, April 10th. They issued an "outperform" rating and a $60.00 target price on the stock. Finally, William Blair restated an "outperform" rating on shares of Exact Sciences in a report on Thursday, February 20th. Two research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Exact Sciences presently has a consensus rating of "Moderate Buy" and an average target price of $70.90.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.